atezolizumab
Researchers aim to validate the AI tool SCORPIO in prospective studies and eventually seek FDA clearance to sell it as a commercial tool in the US.
Roche's Tiragolumab, Tecentriq Combo Misses Overall Survival Endpoint in PD-L1 Positive NSCLC Trial
The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.
Roche Sees Strong Demand for Elevidys Gene Therapy Amid Steady Q3 Pharmaceutical Revenue Growth
Premium
About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.
Roche Reports 5 Percent CER Growth in Pharmaceutical Sales Driven by Strong Phesgo Uptake
In the first half of the year, sales of the injectable formulation of HER2-targeted agent grew 60 percent at CER, compared to H1 2023.
The firm's long-term goal is to develop targeted cancer vaccines for patients at every stage of disease, including pre-cancer.